Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

J. Lange, Beverly; O. Smith, Franklin; H. Feusner, James; Barnard, Dorothy; A. Dinndorf, Patricia; A. Feig, Stephen; A. Heerema, Nyla; Arndt, Carola; Arceci, R.J.; L. Seibel, Nita; Weiman, Margie; E. Dusenbery, Kathryn; Shannon, Kevin; Luna‐Fineman, Sandra; B. Gerbing, Robert; A. Alonzo, Todd

doi:10.1182/blood-2007-04-084293

Public

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group

Published in Blood • Nov 14, 2007

Authors:

Beverly J. Lange

Franklin O. Smith

James H. Feusner

Abstract

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensification. Among 901 patients under age 21 years, 5-year survival wa...

Subject

Idarubicin

Cytarabine

Fludarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!